Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking SEC filings for a development-stage biotechnology company like Aditxt Inc reveals the financial and operational realities behind clinical development programs. With multiple subsidiaries pursuing different immunology platforms, Aditxt's regulatory documents provide insight into how the company allocates resources across Pearsanta's diagnostic initiatives and Adimune's immune tolerance research.
Form 10-Q and 10-K Analysis
Aditxt's quarterly and annual reports detail cash burn rates, which are critical metrics for pre-revenue biotechnology companies. These filings break down research and development expenses by subsidiary, showing how capital flows between the company's immune monitoring and modulation programs. Our AI summaries highlight key financial metrics without requiring you to parse complex biotech accounting.
Material Events Through 8-K Filings
Aditxt files 8-K reports for clinical trial milestones, subsidiary developments, and corporate transactions. For a company with active programs through Pearsanta and Adimune, these material event disclosures provide real-time visibility into program progress, partnership announcements, and strategic pivots that may affect the company's direction.
Insider Transaction Monitoring
Form 4 filings reveal executive and director stock transactions at Aditxt. In development-stage biotechs, insider buying or selling patterns can provide signals about management confidence in upcoming clinical milestones or regulatory decisions.
Proxy Statement Insights
DEF 14A proxy filings disclose executive compensation structures, board composition, and shareholder proposals. For companies executing reverse stock splits and maintaining exchange listing compliance, proxy statements reveal governance decisions and management incentive structures.
Aditxt, Inc. is calling a virtual special stockholder meeting on January 30, 2026 to approve several significant capital and governance changes. Stockholders will vote on approvals related to prior financings, including issuances tied to Series A-1 and Series C-1 convertible preferred stock and multiple warrant agreements, as required by Nasdaq rules. They are also being asked to adopt a 2025 Employee Stock Purchase Plan reserving 200,000 shares and to increase the 2021 Omnibus Equity Incentive Plan share pool to 350,000 shares, which the company states would equal about 19.7% of its common stock. Additional proposals would change the corporate name to “bitXbio, Inc.”, authorize the board to implement a reverse stock split at a ratio between one-for-five (1:5) and one-for-two hundred fifty (1:250) within one year, and permit adjournment of the meeting to solicit more proxies if needed. Holders of Aditxt’s 1,776,023 outstanding common shares as of December 5, 2025 are entitled to one vote per share.
The company filed a prospectus supplement to increase the capacity of its at-the-market common stock offering to up to $20,000,000 in aggregate gross sales, not including shares previously sold, under its existing agreement with H.C. Wainwright & Co., LLC as sales agent.
Previously, the company had registered up to $35,000,000 of common stock for sales under this program, later reduced to $11,840,454, and it has already sold 1,370,607 shares for aggregate gross proceeds of $17,771,951 under prior prospectus supplements. The supplement also notes that the company is currently no longer subject to the offering limits in General Instruction I.B.6 of Form S-3, and that its common stock trades on the Nasdaq Capital Market under the symbol ADTX, where the last reported sale price was $2.24 per share on December 12, 2025.
Aditxt, Inc. (ADTX) reported an insider transaction by its Chief M&A Officer on a Form 4. On 11/25/2025, the officer sold 1 share of Aditxt common stock at a price of $3.2 per share in a transaction coded "S" for sale. After this small tax-related sale, the reporting person held 0 shares of Aditxt common stock directly. The explanation notes that the share was sold for tax-related purposes.
Aditxt, Inc. reported that on November 18, 2025 it issued a press release describing its bitXbio™ strategy and announcing the filing of a preliminary proxy statement on Schedule 14A for a special meeting of stockholders. The proxy statement includes proposals related to the Company’s Employee Stock Purchase Plan and a non-binding advisory vote on amending its Certificate of Incorporation to change the corporate name from “Aditxt, Inc.” to “bitXbio, Inc.” The press release is included as Exhibit 99.1 and incorporated by reference.
Aditxt, Inc. (ADTX) reported very limited revenue and heavy losses in its latest quarter. For the nine months ended September 30, 2025, sales were only $2,770, while the company recorded a net loss of $37,555,792 and used $16,442,686 of cash in operating activities.
Cash on hand was just $163,041, against total liabilities of $20,658,817, resulting in a stockholders’ equity deficit of $8,859,178. Management states there is substantial doubt about Aditxt’s ability to continue as a going concern and notes constraints on raising capital under the Form S-3 “baby shelf” limitation.
A major driver of the loss was a $23,001,919 impairment on its Evofem F-1 Preferred Stock investment, reducing the Evofem-related balance to $7,051,933. The company also faces high-cost debt, lease payment arrears, multiple recent reverse stock splits, and warns that a potential Nasdaq delisting could further hurt liquidity, valuation, and access to financing.
Aditxt, Inc. (ADTX) submitted a Form 12b-25 to notify that its Form 10-Q for the quarter ended September 30, 2025 will be filed late. The company states that the compilation, dissemination and review of the information required for the quarterly report created time constraints that made a timely filing impracticable without undue hardship and expense. Aditxt states that it undertakes the responsibility to file the Form 10-Q no later than 5 days after its original due date under the Rule 12b-25 extension framework.
Aditxt, Inc. (ADTX) approved a 1-for-113 reverse stock split of its issued and outstanding common stock. The split becomes effective at 4:01 p.m. Eastern Time on October 31, 2025, and shares will begin trading on a split-adjusted basis on November 3, 2025. The stated purpose is to bring the company into compliance with Nasdaq’s minimum bid price requirement.
The reverse split does not change the number of authorized shares or the $0.001 par value. Exercise prices and share amounts for outstanding options, restricted stock units, warrants, and plan reserves will be adjusted proportionately, and any fractional shares will be rounded up to the next whole share. The stock will continue trading under the ticker ADTX, and has been assigned a new CUSIP number 007025885.
Aditxt, Inc. reported that Evofem Biosciences terminated the parties’ Amended and Restated Agreement and Plan of Merger, effective immediately. Evofem cited Section 8.1(b)(ii) (the end date having passed) and Section 8.1(b)(iv) (failure to obtain shareholder approval at the
The company stated that no termination fee or other early-termination penalty is payable by Aditxt in connection with a termination under those sections. Certain provisions survive, including the parties’ Non‑Disclosure Agreement dated
Aditxt, Inc. reporting person Christopher J. Porcelli filed an initial Form 3 disclosing his relationship to the company as General Counsel, CPO & CS. The event date noted is 09/30/2025 and the filing is signed on 10/03/2025. The Form 3 shows 0 shares of Common Stock beneficially owned and lists no derivative securities. No indirect ownership or additional holdings are reported on this form.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
